Impact of COVID-19 on the prevalence of dyslipidemia in Ecuador: A cross-sectional study between 2017 and 2022
Objective: To determine changes in the prevalence of dyslipidemias during the pre-COVID-19 and COVID-19 years in three regions of Ecuador. Design: Cross-sectional study. Site: Quito, Guayaquil, and El Coca. Participants: Adults with cholesterol, HDL, LDL, and triglyceride levels at primary care cent...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Elsevier
2025-04-01
|
| Series: | Atención Primaria |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0212656724001495 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387722574135296 |
|---|---|
| author | Josue Rivadeneira Luis Fuenmayor-González Michelle Jácome-García Nancy Flores-Lastra Hugo Delgado Tamara Otzen |
| author_facet | Josue Rivadeneira Luis Fuenmayor-González Michelle Jácome-García Nancy Flores-Lastra Hugo Delgado Tamara Otzen |
| author_sort | Josue Rivadeneira |
| collection | DOAJ |
| description | Objective: To determine changes in the prevalence of dyslipidemias during the pre-COVID-19 and COVID-19 years in three regions of Ecuador. Design: Cross-sectional study. Site: Quito, Guayaquil, and El Coca. Participants: Adults with cholesterol, HDL, LDL, and triglyceride levels at primary care centers from January 2017 to December 2022. Interventions: Not applicable. Main measurements: Data were obtained from five BIODIMED primary care centers. Cholesterol, HDL, LDL, and triglyceride levels were classified according to the ATP III guidelines. Dyslipidemia was considered present when one or more parameters exceeded specific thresholds. Sociodemographic variables and the year of examination were included as independent variables. Results: The study analyzed 110,521 participants’ laboratory results, where 65.3% were males and an average age of 38 ± 12 years. The study spanned the Andean (72.4%), Coast (15.4%), and Amazonic region (12.3%). Pre-pandemic exams constituted 60.9% of the sample. The prevalence of dyslipidemia increased gradually from 43.1% in 2017 to 64.1% in 2022. Cholesterol levels, HDL, and LDL exhibited changes during the pandemic, with an increased risk of hypercholesterolemia, low HDL, and high LDL. Conclusions: During the COVID-19 pandemic, a notable increase in the prevalence of dyslipidemias, including hypercholesterolemia, high triglycerides, and high LDL, was determined across three regions in Ecuador. Resumen: Objetivo: Determinar los cambios en la prevalencia de dislipidemias durante los años previos a la COVID-19 y durante la misma en tres regiones de Ecuador. Diseño: Estudio transversal. Ubicación: Quito, Guayaquil y El Coca. Participantes: Adultos con niveles de colesterol de lipoproteínas de alta densidad (HDL), de lipoproteínas de baja densidad (LDL) y triglicéridos en centros de atención primaria desde enero de 2017 hasta diciembre de 2022. Intervenciones: No aplica. Principales mediciones: Los datos se obtuvieron de cinco centros de atención primaria BIODIMED. Los niveles de colesterol HDL, LDL y triglicéridos se clasificaron según las directrices del Adult Treatment Panel III (ATP III). Se consideró que existía dislipidemia cuando uno o más parámetros superaban los umbrales específicos. Se incluyeron variables sociodemográficas y el año de examen como variables independientes. Resultados: El estudio analizó los resultados de laboratorio de 110.521 participantes, donde el 65,3% eran hombres y la edad promedio era de 38 ± 12 años. El estudio abarcó la región Andina (72,4%), la Costa (15,4%) y la región Amazónica (12,3%). Los exámenes prepandemia constituyeron el 60,9% de la muestra. La prevalencia de dislipidemia aumentó gradualmente del 43,1% en 2017 al 64,1% en 2022. Los niveles de colesterol HDL y LDL mostraron cambios durante la pandemia, con un riesgo aumentado de hipercolesterolemia, HDL bajo y LDL alto. Conclusiones: Durante la pandemia de COVID-19, se determinó un aumento notable en la prevalencia de dislipidemias, incluyendo hipercolesterolemia, triglicéridos altos y LDL alto, en tres regiones de Ecuador. |
| format | Article |
| id | doaj-art-1da326f2417c4416aef21bd912df0af5 |
| institution | Kabale University |
| issn | 0212-6567 |
| language | Spanish |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Atención Primaria |
| spelling | doaj-art-1da326f2417c4416aef21bd912df0af52025-08-20T03:44:27ZspaElsevierAtención Primaria0212-65672025-04-0157410300710.1016/j.aprim.2024.103007Impact of COVID-19 on the prevalence of dyslipidemia in Ecuador: A cross-sectional study between 2017 and 2022Josue Rivadeneira0Luis Fuenmayor-González1Michelle Jácome-García2Nancy Flores-Lastra3Hugo Delgado4Tamara Otzen5Universidad de La Frontera, Doctorado en Ciencias Médicas, Temuco, Chile; Zero Biomedical Research, Quito, Ecuador; Núcleo Milenio de Sociomedicina, Santiago, ChileZero Biomedical Research, Quito, Ecuador; Universidad Central del Ecuador, Facultad de Ciencias Médicas, Quito, EcuadorZero Biomedical Research, Quito, EcuadorZero Biomedical Research, Quito, Ecuador; Universidad De Especialidades Espíritu Santo, Facultad de Ciencias de la Salud-Nutrición, Guayaquil, EcuadorUniversidad de La Frontera, Doctorado en Ciencias Médicas, Temuco, ChileUniversidad de La Frontera, Doctorado en Ciencias Médicas, Temuco, Chile; Núcleo Milenio de Sociomedicina, Santiago, Chile; Universidad de La Frontera, Facultad de Medicina, Departamento de Especialidades Médicas, Temuco, Chile; Corresponding author.Objective: To determine changes in the prevalence of dyslipidemias during the pre-COVID-19 and COVID-19 years in three regions of Ecuador. Design: Cross-sectional study. Site: Quito, Guayaquil, and El Coca. Participants: Adults with cholesterol, HDL, LDL, and triglyceride levels at primary care centers from January 2017 to December 2022. Interventions: Not applicable. Main measurements: Data were obtained from five BIODIMED primary care centers. Cholesterol, HDL, LDL, and triglyceride levels were classified according to the ATP III guidelines. Dyslipidemia was considered present when one or more parameters exceeded specific thresholds. Sociodemographic variables and the year of examination were included as independent variables. Results: The study analyzed 110,521 participants’ laboratory results, where 65.3% were males and an average age of 38 ± 12 years. The study spanned the Andean (72.4%), Coast (15.4%), and Amazonic region (12.3%). Pre-pandemic exams constituted 60.9% of the sample. The prevalence of dyslipidemia increased gradually from 43.1% in 2017 to 64.1% in 2022. Cholesterol levels, HDL, and LDL exhibited changes during the pandemic, with an increased risk of hypercholesterolemia, low HDL, and high LDL. Conclusions: During the COVID-19 pandemic, a notable increase in the prevalence of dyslipidemias, including hypercholesterolemia, high triglycerides, and high LDL, was determined across three regions in Ecuador. Resumen: Objetivo: Determinar los cambios en la prevalencia de dislipidemias durante los años previos a la COVID-19 y durante la misma en tres regiones de Ecuador. Diseño: Estudio transversal. Ubicación: Quito, Guayaquil y El Coca. Participantes: Adultos con niveles de colesterol de lipoproteínas de alta densidad (HDL), de lipoproteínas de baja densidad (LDL) y triglicéridos en centros de atención primaria desde enero de 2017 hasta diciembre de 2022. Intervenciones: No aplica. Principales mediciones: Los datos se obtuvieron de cinco centros de atención primaria BIODIMED. Los niveles de colesterol HDL, LDL y triglicéridos se clasificaron según las directrices del Adult Treatment Panel III (ATP III). Se consideró que existía dislipidemia cuando uno o más parámetros superaban los umbrales específicos. Se incluyeron variables sociodemográficas y el año de examen como variables independientes. Resultados: El estudio analizó los resultados de laboratorio de 110.521 participantes, donde el 65,3% eran hombres y la edad promedio era de 38 ± 12 años. El estudio abarcó la región Andina (72,4%), la Costa (15,4%) y la región Amazónica (12,3%). Los exámenes prepandemia constituyeron el 60,9% de la muestra. La prevalencia de dislipidemia aumentó gradualmente del 43,1% en 2017 al 64,1% en 2022. Los niveles de colesterol HDL y LDL mostraron cambios durante la pandemia, con un riesgo aumentado de hipercolesterolemia, HDL bajo y LDL alto. Conclusiones: Durante la pandemia de COVID-19, se determinó un aumento notable en la prevalencia de dislipidemias, incluyendo hipercolesterolemia, triglicéridos altos y LDL alto, en tres regiones de Ecuador.http://www.sciencedirect.com/science/article/pii/S0212656724001495COVID-19DislipidemiasHipercolesterolemiaHipertrigliceridemiaEstudios transversalesEcuador |
| spellingShingle | Josue Rivadeneira Luis Fuenmayor-González Michelle Jácome-García Nancy Flores-Lastra Hugo Delgado Tamara Otzen Impact of COVID-19 on the prevalence of dyslipidemia in Ecuador: A cross-sectional study between 2017 and 2022 Atención Primaria COVID-19 Dislipidemias Hipercolesterolemia Hipertrigliceridemia Estudios transversales Ecuador |
| title | Impact of COVID-19 on the prevalence of dyslipidemia in Ecuador: A cross-sectional study between 2017 and 2022 |
| title_full | Impact of COVID-19 on the prevalence of dyslipidemia in Ecuador: A cross-sectional study between 2017 and 2022 |
| title_fullStr | Impact of COVID-19 on the prevalence of dyslipidemia in Ecuador: A cross-sectional study between 2017 and 2022 |
| title_full_unstemmed | Impact of COVID-19 on the prevalence of dyslipidemia in Ecuador: A cross-sectional study between 2017 and 2022 |
| title_short | Impact of COVID-19 on the prevalence of dyslipidemia in Ecuador: A cross-sectional study between 2017 and 2022 |
| title_sort | impact of covid 19 on the prevalence of dyslipidemia in ecuador a cross sectional study between 2017 and 2022 |
| topic | COVID-19 Dislipidemias Hipercolesterolemia Hipertrigliceridemia Estudios transversales Ecuador |
| url | http://www.sciencedirect.com/science/article/pii/S0212656724001495 |
| work_keys_str_mv | AT josuerivadeneira impactofcovid19ontheprevalenceofdyslipidemiainecuadoracrosssectionalstudybetween2017and2022 AT luisfuenmayorgonzalez impactofcovid19ontheprevalenceofdyslipidemiainecuadoracrosssectionalstudybetween2017and2022 AT michellejacomegarcia impactofcovid19ontheprevalenceofdyslipidemiainecuadoracrosssectionalstudybetween2017and2022 AT nancyfloreslastra impactofcovid19ontheprevalenceofdyslipidemiainecuadoracrosssectionalstudybetween2017and2022 AT hugodelgado impactofcovid19ontheprevalenceofdyslipidemiainecuadoracrosssectionalstudybetween2017and2022 AT tamaraotzen impactofcovid19ontheprevalenceofdyslipidemiainecuadoracrosssectionalstudybetween2017and2022 |